Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barratt

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Pain Research (Lausanne, Switzerland)|July 9, 2026
Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environmentCharlotte Helen Johnston, Danila Marini, Stefan T Musolino, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 1996
Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated proteinB A Ballif, N V Mincek, J T Barratt, et al.
British Journal of Clinical Pharmacology|June 18, 2019
High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptomsAndrew A Somogyi, Daniel T Barratt, Elizabeth J Phillips, et al.
Pain|September 21, 2016
Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative painAndrew A Somogyi, Alex T Sia, Ene-Choo Tan, et al.
Clinical Pharmacology and Therapeutics|May 13, 2022
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory DepressionAhmad Y Abuhelwa, Andrew A Somogyi, Colleen K Loo, et al.
Pharmacogenetics and Genomics|January 29, 2014
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS studyDaniel T Barratt, Benedikte Bandak, Pål Klepstad, et al.
Journal of Neurochemistry|June 16, 2012
Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury modelPeter M Grace, Daniel Hurley, Daniel T Barratt, et al.
Pharmacogenetics and Genomics|May 17, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safetyJoseph D Tucci, Paul P Pumuye, Nuala A Helsby, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogeneticsDaniel T Barratt, Janet K Coller, Richard Hallinan, et al.
Clinical Pharmacokinetics|December 21, 2016
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia PatientsDaniel T Barratt, Hannah K Cox, Andrew Menelaou, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Pain Research (Lausanne, Switzerland)|July 9, 2026
Feasibility and reliability of pressure algometry for mechanical nociceptive threshold quantification in lambs in a field environmentCharlotte Helen Johnston, Danila Marini, Stefan T Musolino, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 1996
Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated proteinB A Ballif, N V Mincek, J T Barratt, et al.
British Journal of Clinical Pharmacology|June 18, 2019
High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptomsAndrew A Somogyi, Daniel T Barratt, Elizabeth J Phillips, et al.
Pain|September 21, 2016
Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative painAndrew A Somogyi, Alex T Sia, Ene-Choo Tan, et al.
Clinical Pharmacology and Therapeutics|May 13, 2022
Population Pharmacokinetics and Pharmacodynamics of the Therapeutic and Adverse Effects of Ketamine in Patients With Treatment-Refractory DepressionAhmad Y Abuhelwa, Andrew A Somogyi, Colleen K Loo, et al.
Pharmacogenetics and Genomics|January 29, 2014
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS studyDaniel T Barratt, Benedikte Bandak, Pål Klepstad, et al.
Journal of Neurochemistry|June 16, 2012
Harnessing pain heterogeneity and RNA transcriptome to identify blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic constriction injury modelPeter M Grace, Daniel Hurley, Daniel T Barratt, et al.
Pharmacogenetics and Genomics|May 17, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safetyJoseph D Tucci, Paul P Pumuye, Nuala A Helsby, et al.
Pharmacogenomics and Personalized Medicine|December 11, 2012
ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogeneticsDaniel T Barratt, Janet K Coller, Richard Hallinan, et al.
Clinical Pharmacokinetics|December 21, 2016
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia PatientsDaniel T Barratt, Hannah K Cox, Andrew Menelaou, et al.
Pageof 4